Will conduct the first comprehensive in-depth analysis of outsourced clinical research quality.
Responding to growing interest in clinical trial outsourcing quality and solutions, Applied Clinical Trials announced today the first comprehensive in-depth analysis of the quality of outsourced clinical research. The groundbreaking research project will survey sponsor managers and executives involved to determine their view of the state of the outsourcing industry that continues to grow even faster than overall clinical research.
Applied Clinical Trials will collaborate with CRO Analytics on the project, utilizing its PerformerTM platform to collect the data. CRO Analytics’ Chief Scientific Officer Dr. Michael Howley will lead the analysis and reporting of results.
Said Lisa Henderson, Applied Clinical Trials Editor-in-Chief, “Perhaps more than any other topic clinical trial outsourcing solutions are of constant interest to our readers. The environment is evolving so rapidly that we thought it important to step back and assess where it stands in a comprehensive manner.” Added, Henderson, “The research will help us establish a baseline that can be revisited in the future to as well as provide a robust data set that will enable us to drill down and report on key drivers of clinical research quality.”
Current sponsor personnel will be invited to register for the project beginning the week of June 9. Once registered, they will be able to select any active or recently completed Phase II-IV trial from the clinicltrials.gov listings to assess.
Participants can then choose from five assessments (Sales and Contracting, Study Start-Up, Study Conduct, Study Close-Out, and Overall Performance) and may complete as many assessments for as many trials as they are qualified. All participants will remain anonymous but will be confirmed as sponsor personnel and all results will be aggregated. No individual sponsors, trials, or research service providers identified.
Explained Henderson, “The intent is to take stock of where we are as an industry—not to call out or measure individual organizations. We’re excited about this because nobody has really looked at outsourcing quality in such a holistic, rigorous fashion before.”
Peter Malamis, CEO of CRO Analytics said the company was honored to be part of the effort, “Our team has put a lot of time over the last three years developing Performer. Our statistically validated assessments and cloud-based platform are uniquely suited for this type of research and we look forward to helping Applied Clinical Trials provide an important new perspective on this critical area.”
To learn more, please visit www.appliedclinicaltrialsonline.com or www.croanalytics.com.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.